Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Journal for ImmunoTherapy of Cancer

Figure 3

From: Melanoma-derived Wnt5a conditions dendritic cells to promote regulatory T cell differentiation via the upregulation of indoleamine 2,3-dioxygenase: novel pharmacological strategies for augmenting immunotherapy efficacy

Figure 3

Wnt5a conditions DCs to drive regulatory T-cell cifferentiation. A. Schematic of in vitro Treg assay. B. Wnt5a-conditioned DCs stimulate CD4+FoxP3+ Treg differentiation in vitro following co-incubation with total splenic CD4+ T cells at a 1:1, 5:1 or 10:1 T cell to DC ratio. CD4+FoxP3+ Tregs were quantitated by flow cytometry. Representative of 3 independent experiments. C. DCs pre-conditioned for 24 and 48 hrs stimulate CD4+FoxP3+ Treg differentiation in vitro following co-incubation with naive splenic CD4+CD62L+ T cells. DCs were pretreated Wnt3a or Wnt5a for 24 or 28 hrs then co-incubated with splenic naïve CD4+ T cells with or without the IDO inhibitor, 1-MT. CD4+FoxP3+ Tregs were quantitated by flow cytometry. Performed in triplicate. Data is normalized to untreated DC condition. Representative of 3 independent experiments. P values based on a two-way ANOVA.

Back to article page